Oral Semaglutide: The OASIS Trial Program That Made the GLP-1 Pill Real

In December 2025, the FDA approved oral Wegovy — the first GLP-1 pill for weight management. The OASIS 4 trial showed 16.6% weight loss at 64 weeks with full adherence, rivaling injectable semaglutide. Here's the complete data from the trial program that eliminated the needle.

For most of the GLP-1 era, the drugs required weekly injections. Rybelsus (oral semaglutide 7 mg and 14 mg) existed for diabetes, but its weight loss effect was modest compared to injectable Wegovy at 2.4 mg. The OASIS clinical trial program changed this by testing a higher oral dose — 25 mg and 50 mg — specifically for weight management. OASIS 4, the pivotal trial for the 25 mg dose, delivered results that were statistically comparable to injectable semaglutide 2.4 mg.

On December 22, 2025, the FDA approved oral Wegovy (semaglutide 25 mg daily pill) for chronic weight management — the first oral GLP-1 drug approved for this indication. Novo Nordisk launched the product in the US in January 2026.

OASIS 4: The Registration Trial

OASIS 4 (NCT05564117) was a 71-week, double-blind, randomized, placebo-controlled Phase 3 trial conducted at 22 sites across four countries. It enrolled 307 adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. Participants were randomized 2:1 to oral semaglutide 25 mg once daily or placebo, alongside lifestyle intervention.

Treatment included a 12-week dose escalation period followed by continued therapy through week 64, with a 7-week off-treatment follow-up. The primary endpoint was percentage change in body weight at week 64.

How It Compares to Injectable Semaglutide

The 16.6% weight loss (adherent population) is comparable to the 12.4-percentage-point placebo-adjusted difference seen in STEP 1 with injectable semaglutide 2.4 mg weekly, and to the 12.7-percentage-point difference seen in OASIS 1 with the higher 50 mg oral dose. Post-hoc pooled analyses presented at ObesityWeek 2025 confirmed that oral and injectable semaglutide produced comparable weight loss and cardiometabolic outcomes.

The cardiometabolic improvements were substantial: significant reductions in HbA1c, fasting glucose, fasting insulin, C-reactive protein, triglycerides, and blood pressure. Women across all menopause stages saw 15–18% mean weight loss, with over half losing more than 15% of body weight.

The Broader OASIS Program

OASIS 4 is one trial in a larger clinical development program. OASIS 1 tested oral semaglutide 50 mg, showing even greater weight loss (approximately 17.4% with adherence). OASIS 2 through OASIS 5 evaluate different doses and populations, including patients with type 2 diabetes. The FDA's approval was based primarily on OASIS 4 data for the 25 mg dose.

What This Means for Patients

The oral formulation removes the injection barrier — a significant obstacle for many patients. GLP-1 drugs have historically been limited to weekly subcutaneous injections, which some patients refuse or tolerate poorly. A daily pill that produces comparable weight loss and metabolic improvement opens the drug class to a much larger population.

The tradeoff is daily dosing (versus weekly injection) and the absorption requirements: oral semaglutide must be taken on an empty stomach with a small amount of water, with no food for 30 minutes afterward. Adherence to these instructions affects absorption and, consequently, efficacy.